The patent, to be issued on July 9, 2013, covers an injection system for methotrexate and subcutaneous administration of the drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Otrexup is a combination product for the delivery of methotrexate for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, using Medi-Jet technology and for testosterone replacement therapy using VIBEX QST.
Antares president, chief executive officer, patent co-inventor Paul Wotton said, "The granting of this broad and comprehensive patent is an important achievement in our commercialization strategy and one of a number of patent applications we have filed addressing the use of an auto-injector platform in combination with a wide range of product candidates, including those in our growing pipeline, such as QST being developed for testosterone replacement therapy."